Focused On-demand Library for MAP kinase-activated protein kinase 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

p38-regulated/activated protein kinase

Alternative UPACC:

Q8IW41; B3KVA5; O60491; Q86X46; Q9BVX9; Q9UG86


MAP kinase-activated protein kinase 5, also known as p38-regulated/activated protein kinase, plays a pivotal role in mTORC1 signaling and post-transcriptional regulation. It phosphorylates several key proteins including FOXO3, ERK3/MAPK6, and p53/TP53, acting as a tumor suppressor and mediating Ras-induced senescence. Its involvement in the atypical MAPK signaling pathway underscores its complex regulatory functions in cellular processes.

Therapeutic significance:

Given its role in tumor suppression and regulation of critical signaling pathways, MAP kinase-activated protein kinase 5 holds significant therapeutic potential. Understanding its mechanisms could lead to novel interventions for Neurocardiofaciodigital syndrome, characterized by developmental delay and congenital defects, and potentially other diseases linked to dysregulated mTORC1 signaling and cellular senescence.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.